<DOC>
	<DOCNO>NCT00101270</DOCNO>
	<brief_summary>This phase I trial study side effect best dose oxaliplatin give together irinotecan treat young patient refractory solid tumor lymphomas . Drugs use chemotherapy , oxaliplatin irinotecan , work different way stop growth cancer cell , either kill cell stop dividing . Oxaliplatin may help irinotecan kill cancer cell make cancer cell sensitive drug . Giving oxaliplatin together irinotecan may kill cancer cell .</brief_summary>
	<brief_title>Oxaliplatin Irinotecan Treating Young Patients With Refractory Solid Tumors Lymphomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose oxaliplatin administer irinotecan pediatric patient refractory solid tumor lymphomas . II . Determine toxic effect regimen patient . III . Determine pharmacokinetics regimen patient . SECONDARY OBJECTIVES : I . Determine , preliminarily , antitumor activity regimen patient . II . Correlate UGT BCRP genotype toxicity regimen patient . OUTLINE : This multicenter , dose-escalation study oxaliplatin . Patients receive oxaliplatin IV 2 hour day 1 8 irinotecan IV 1 hour day 1-5 8-12 . Treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Optic Nerve Glioma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm refractory malignant solid tumor lymphoma Intrinsic brain stem tumor optic pathway tumor require histologic verification No known curative therapy therapy proven prolong survival acceptable quality life exist Measurable evaluable disease Evaluable disease define tumor measure use ruler caliper , assess determine disease progression complete response , follow : Positive lesion metaiodobenzylguanidine ( MIBG ) bone scan Metastatic bone marrow disease Elevated tumor marker Presence malignant pleural effusion No leukemia Performance status Karnofsky 50100 % ( patient &gt; 10 year age ) Performance status Lansky 50100 % ( patient ≤ 10 year age ) Not specify Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 5 time ULN Albumin ≥ 2 g/dL Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine base age follow : No great 0.8 mg/dL ( patient age 5 ) No great 1.0 mg/dL ( patient age 6 10 ) No great 1.2 mg/dL ( patient age 11 15 ) No great 1.5 mg/dL ( patient age 16 ) No arrhythmia EKG No evidence dyspnea rest No exercise intolerance Pulse oximetry &gt; 94 % room air evidence pulmonary fibrosis chest radiograph* CT scan Not pregnant Negative pregnancy test Fertile patient must use effective contraception Weight ≥ 10 kg Neurologic deficits relatively stable ≥ 1 week study entry ( patient CNS tumor ) No electrolyte ( e.g. , sodium , potassium , bicarbonate , calcium , magnesium , phosphate ) abnormality ≥ grade 2 ( electrolyte supplementation allow ) No uncontrolled infection No history lifethreatening allergy camptothecin derivative platinum agent No sensory motor peripheral neuropathy ≥ grade 2 No elevation amylase lipase ≥ grade 2 Able tolerate enteral medication ( e.g. , cefixime , cefpodoxime , loperamide ) Recovered prior immunotherapy At least 7 day since prior hematopoietic growth factor At least 7 day since prior antineoplastic biologic therapy Prior stem cell transplantation rescue without totalbody irradiation ( TBI ) allow provide ≥ 3 month elapse evidence active graftversushost disease No concurrent immunotherapy No concurrent biologic therapy More 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) recover No prior oxaliplatin No concurrent chemotherapy Concurrent steroid allow provide dose stable ≥ 7 day study entry See Biologic therapy Recovered prior radiotherapy At least 2 week since prior local palliative small port radiotherapy At least 6 month since prior TBI At least 6 month since prior craniospinal , whole spinal , whole lung/abdominal radiotherapy At least 6 month since prior radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial radiotherapy bone marrow No concurrent radiotherapy No concurrent investigational drug No concurrent anticancer therapy No concurrent cephalosporin antibiotics No concurrent use follow : Phenytoin Carbamazepine Oxcarbazepine Barbiturates Rifampin Phenobarbital Azole antifungal agent Aprepitant Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>